{"disease":{"id":"hereditary-angioneurotic-edema","name":"Hereditary angioneurotic edema","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":7,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"lanadelumab","indication_name":"Hereditary angioneurotic edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Takhzyro","generic_name":"LANADELUMAB","company_name":"Dyax Corp","drug_phase":"marketed","molecular_target":"plasma kallikrein","drug_class":"Plasma Kallikrein Inhibitor [EPC]","quality_score":66,"revenue":"1500","mechanism":"Lanadelumab-flyo binds and inhibits plasma kallikrein, reducing bradykinin generation and controlling angioedema in HAE."},{"drug_id":"firazyr","indication_name":"Hereditary angioneurotic edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Firazyr","company_name":"Sebastian Videla","drug_phase":"marketed","molecular_target":"B1 bradykinin receptor, B2 bradykinin receptor, B1 bradykinin receptor","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"lanadelumab-flyo","indication_name":"Hereditary angioneurotic edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TAKHZYRO","generic_name":"LANADELUMAB-FLYO","company_name":"DYAX CORP.","drug_phase":"marketed","molecular_target":"Plasma kallikrein","drug_class":"Plasma Kallikrein Inhibitor [EPC]","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"berotralstat","indication_name":"Hereditary angioneurotic edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Orladeyo","generic_name":"BEROTRALSTAT","company_name":"Biocryst","drug_phase":"marketed","molecular_target":"Plasma kallikrein","drug_class":"Plasma Kallikrein Inhibitor","quality_score":55,"revenue":null,"mechanism":"Orladeyo works by blocking the plasma kallikrein enzyme, which is involved in the production of bradykinin, a key mediator of HAE symptoms."},{"drug_id":"stanozolol","indication_name":"Hereditary angioneurotic edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Winstrol","generic_name":"STANOZOLOL","company_name":"","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"stanozolol","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ecallantide","indication_name":"Hereditary angioneurotic edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kalbitor","generic_name":"ECALLANTIDE","company_name":"Dyax Corp.","drug_phase":"marketed","molecular_target":"Plasma kallikrein","drug_class":"Plasma Kallikrein Inhibitor [EPC]","quality_score":62,"revenue":null,"mechanism":"Kalbitor works by blocking the plasma kallikrein enzyme, which is involved in the production of bradykinin, a key mediator of HAE symptoms."},{"drug_id":"icatibant","indication_name":"Hereditary angioneurotic edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Firazyr","generic_name":"ICATIBANT","company_name":"Takeda","drug_phase":"marketed","molecular_target":"B2 bradykinin receptor","drug_class":"Bradykinin B2 Receptor Antagonist","quality_score":48,"revenue":null,"mechanism":"Firazyr works by blocking the action of bradykinin, a protein that causes blood vessels to swell and leads to symptoms of HAE."}],"pipeline":[],"offLabel":[],"totalMarketed":7,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}